PBT434 inhibits alpha- synuclein in the brain., page-14

Originallypostedbyskint

pivalde,Iagreetheinfofromthetrialleavesroomforguesswork.ItisinterestingthatbothBIIBandAstraZenica/TakedaaregoingdirectlyafterA-Synintheveryearlystagesofthedisease(Parkinsons),whenA-SynlevelsareapparentlydroppingintheCSF(spinalfluid).
ThisisstillearlydayswithBIIBrecruitingphase2andAZjuststartingphase1,buttomeitlookslikePBT434hasmorechanceofsuccess,withawiderrangeofeffects,suchasthosebeinginvestigatedbytheFairpark2trialwitharelateddrug.TheyarenotevenreportingA-SynasfarasIcansee.
AllIMOasanonmedicalobserver.

Skint, the guesswork is helped at least a bit by the animal study. PBT434 cleared alpha-synuclein from the brain of the animals and ATH for sure knows what did happen in the CSF at the same time in these animals. Perhaps there was first a lot of synuclein in the CFS of the animals after starting PBT434 and gradually less of it. So my guess is that in the phase 1 study there was an increase of alpha-synuclein in the CFS already after 1 week on PBT434 and that is already a sign of "an inhibition" of alpha-synuclein causing harm in the brain. This is still guesswork, however. Brain biopsies would be beneficial.